thedevelopmentofanti-hiv-1drugs

humanimmunodeficiencyvirustype1(hiv-1)isthecausativeagentofacquiredimmunodeficiencydiseasesyndrome(aids).？afterover26yearsofefforts,thereisstillnotatherapeuticcureoraneffectivevaccineagainsthiv/aids.？theclinicalmanagementofhiv-1infectedpeoplelargelyreliesonantiretroviraltherapy(art).？althoughhighlyactiveantiretroviraltherapy(haart)hasprovidedaneffectivewaytotreataidspatients,thehugeburdenofartindevelopingcountries,togetherwiththeincreasingincidenceofdrugresistantvirusesamongtreatedpeople,callsforcontinuouseffortsforthedevelopmentofanti-hiv-1drugs.？currently,fourclassesofover30licensedantiretrovirals(arvs)andcombinationregimensofthesearvsareinuseclinicallyincluding:reversetranscriptaseinhibitors(rtis)(e.g.nucleosidereversetranscriptaseinhibitors,nrtis;andnon-nucleosidereversetranscriptaseinhibitors,nnrtis),proteaseinhibitors(pis),integraseinhibitorsandentryinhibitors(e.g.fusioninhibitorsandccr5antagonists).？here,weintendtoprovideupdated？？informationofcurrentlyavailableantiretroviraldrugsforarttopromotethedevelopmentofnovelanti-hiv-1drugs.